TFFP - TFF Pharmaceuticals Inc. Debt to Book Capitalization Ratio

Graphic logo of TFF Pharmaceuticals Inc. (TFFP)

TFF Pharmaceuticals (TFFP) is currently executing a hard pivot, cutting costs and seeking to license its thin-film drying technology. Analyzing the chart on GURU.Markets, we see that the company's total debt-to-equity ratio currently stands at 0.02. The company is also developing inhalation powders through biolabs and creating dry vaccine formulations in collaboration with external drug developers.

TFFP (TFF Pharmaceuticals, Inc) Debt to Book Value history from 07/04/2022 to 12/21/2024
Core merchandise of TFF Pharma

A defensive portfolio requires strict monitoring of the issuer's financial stability. This indicator compares total liabilities to the book value of equity to determine the business's degree of dependence on borrowed funds. For TFF Pharmaceuticals (TFFP), this balance is critical when implementing automated thin-film freezing lines. A high debt load could limit the scaling of robotic production. The trend in the total debt-to-book capitalization ratio reflects the company's current margin of safety.

Competitors of TFF Pharmaceuticals

Debts to Book Capitalization HLN (Haleon plc)|kenvue.com - Debts to Book Capitalization|Debt to Book Capitalization Ratio Verona Pharma (VRNA)|MENS: Debt to Net Assets Ratio|LGND (Ligand Pharma) - Debt to Book Capitalization Ratio|Amneal Corp (AMRX) - Debt to Book Value|PRGO (Perrigo Company plc) - Debts to Book Capitalization|Debts to Book Capitalization alvotech.com (ALVO)|Liquidia (LQDA) - Debt to Book Value|Debt to Net Assets Ratio GLPG (Galapagos N.V.)|ANIP: Debt to Book Capitalization Ratio|MNKD - Debts to Book Value|Debt to Book Value Amphastar Pharmaceuticals AMPH|PCRX - Debt to Book Capital|Debts to Book Capitalization ARS Pharmaceuticals, Inc. SPRY|Theravance Biopharma Inc (TBPH) - Debt to Net Assets Ratio|Debts to Book Capitalization AQST (Aquestive Pharma)|Debts to Book Value SCPH|Tectonic Therapeutic, Inc. (TECX) - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio tonixpharma.com TNXP|Debt to Book Value China SXT Pharmaceuticals, Inc. (SXTC)|Debt to Book Capital Eupraxia Pharmaceuticals, Inc. EPRX|Debts to Book Capitalization BioHarvest|EXOZ - Debts to Book Capitalization Ratio|Debts to Book Capitalization oramed.com (ORMP)|Debts to Book Capitalization Ratio Entera Bio|HYFT - Debt to Book Value|Debt to Net Assets Ratio ABVC|CPIX - Debt to Book Capitalization Ratio|Debts to Book Capitalization Ratio Quantum BioPharma Corp (QNTM)|Debts to Book Capitalization FibroGen, Inc.|Debt to Net Assets Ratio telomirpharma.com TELO|Rani Therapeutics Inc - Debts to Book Capitalization|SNYR: Debts to Book Capitalization|Debt to Book Capitalization Ratio rallybio.com RLYB|LEXX (Lexaria Bioscience Corp.) - Debt to Net Assets Ratio|Debt to Book Capitalization Ratio PULM|Debt to Book Value Pheton|Debts to Book Capitalization APM|Debts to Book Capitalization Lyra Therapeutics Inc. (LYRA)|Impact BioMedical Inc - Debts to Book Capitalization|Debt to Book Value TNF Pharmaceuticals Inc. TNFA|YCBD (cbdMD Corp) - Debts to Book Capitalization|painreform.com (PRFX) - Debts to Book Value|CYTO: Debt to Book Value|Debts to Book Capitalization Lipella Pharmaceuticals Inc|Optinose (OPTN) - Debt to Book Value|Debt to Book Capital Pieris Pharma|PROC (Procaps Group S.A.) - Debts to Book Capitalization|Debts to Net Assets petrospharma.com (PTPI)|Qilian International Holding - Debts to Book Capitalization|Debt to Book Value Acelyrin Inc. SLRN